|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
,






,
* PRESTO, Japan Science and Technology Agency, Saitama, Japan;
Division of Molecular and Cellular Immunology, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan;
Department of Biomolecular Sciences, Faculty of Medicine, Saga University, Saga, Japan; and
Research Institute for Diseases of the Chest and
¶ Department of Parasitology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| Abstract |
|---|
|
|
|---|
production was also enhanced in WSX-1/ mice, albeit at a low concentration. The cytokine overproduction, thus, seems independent from the Th1-promoting property of WSX-1. These results demonstrated that IL-27/WSX-1 also plays an important role in the down-regulation of airway hyper-reactivity and lung inflammation during the development of allergic asthma through its suppressive effect on cytokine production. | Introduction |
|---|
|
|
|---|
, a Th1-type cytokine, has also been implicated in the pathogenesis (3). Among Th2 cytokines, IL-4 participates in Th2 cell differentiation (4), IgE isotype class switching (5), and airway remodeling containing enhanced collagen synthesis by fibroblasts (6). IL-5 promotes differentiation and migration of eosinophils (7, 8, 9). IL-13 is highly expressed in Th2 cells from asthma patients (10) and plays a role in the development of allergic asthma (11, 12) by acting on epithelial cells to produce AHR and mucus production (13). These results indicate that inappropriate development of Th2 responses plays a central role in the development of asthma. Although Th1 cells have been shown to prevent allergic disease by turning down the activity of Th2 cells (14, 15, 16), a contradictory report has shown that Ag-specific Th1 cells induced severe airway inflammation and acute lung pathology (3), raising controversy about the role of Th1 cytokines in AHR.
WSX-1 is a class I cytokine receptor with homology to gp130 of IL-6R and to IL-12R families (17). WSX-1 is highly expressed in spleen, thymus, and lymph nodes, particularly in the CD4+ T cell and NK cell compartments (17, 18, 19). IL-27, a heterodimeric cytokine consisting of p28 and EBV-induced gene 3 (EBI3), has been identified as a ligand for WSX-1, inducing the proliferation of and IFN-
production by naive CD4+ T cells in synergy with IL-12 (20). Takeda et al. (21) demonstrated that IL-27/WSX-1 interaction induces T-bet and IL-12R
2 expression through STAT1 activation. Experiments using WSX-1-deficient (WSX-1/) mice revealed that WSX-1 plays an important role in Th1 differentiation during infection with some intracellular pathogens. Namely, WSX-1/ mice showed increased susceptibility to infection with Listeria monocytogenes and Leishmania major due to impaired IFN-
production (18, 19). In addition, Artis et al. (22) revealed that WSX-1 is required for suppression of the early IL-4 responses and the resultant Th1 promotion during L. major infection. These results clearly indicated that WSX-1 signaling acts before IL-12 to provide IL-12 responsiveness in naive CD4+ cells during the Th1 commitment of the cells. More recently, Villarino et al. (23) reported an interesting phenomena that WSX-1/ mice infected with Toxoplasma gondii exhibited lethal inflammation mediated by hyperactivated CD4+ T cells. Infection with Trypanosoma cruzi also induced severe liver injury accompanied by overproduction of proinflammatory cytokines in WSX-1/ mice (24). A similar anti-inflammatory property of WSX-1 has been observed in mice infected with Mycobacterium tuberculosis (25). These findings have revealed novel functions of WSX-1 as a down-regulator of inflammatory cytokine production.
Although roles and mechanisms of WSX-1 in promotion or inhibition of immune responses against pathogenic infection has been clear, little is known about the importance of WSX-1 in diseases other than infection. In the current study we investigated the influence of WSX-1 deficiency in a murine model of asthma. We found that WSX-1/ mice exhibited enhanced asthmatic phenotypes, including AHR, pulmonary inflammation with mucus overproduction and eosinophilic infiltration, and increased Ag-specific IgE in response to Ag challenge. Moreover, Th2 cytokine productions were enhanced in challenged WSX-1/ mice compared with wild-type (WT) mice. These results indicated that WSX-1 plays an important role in the regulation of allergic inflammation by cytokine production.
| Materials and Methods |
|---|
|
|
|---|
WSX-1/ mice were generated as described previously by Yoshida et al. (19) and were backcrossed more than nine times to C57BL/6 mice (continual backcrossing). Mice were housed in microisolator cages and were used between 8 and 14 wk of age. Age- and sex-matched WT C57BL/6 mice (Seac Yoshitomi) were used as controls. All experiments were approved by the institutional animal research committee of Kyushu University and conformed to the animal care guidelines of the American Physiologic Society.
Immunization and airway challenge with OVA
WT or WSX-1/ female mice were immunized i.p. twice with 20 µg of OVA (0.1 ml of 200 µg/ml in saline) adsorbed to aluminum potassium sulfate (Imject Alum; Pierce) at a 2-wk interval. On days 28, 29, and 30, the sensitized mice were challenged with a 1% (w/v) OVA/saline aerosol for 30 min in a chamber (24 x 17 x 17 cm). Thirty-six hours after the last aerosol challenge, measurements of airway responsiveness and other parameters were performed.
Measurement of airway responsiveness
Mice were anesthetized with a mixture of ketamine and sodium pentobarbital i.p., and their tracheas were cannulated via tracheotomy. The animals were ventilated mechanically (model 687; Harvard Apparatus), with a tidal volume of 0.01 ml/g body weight (
0.3 ml) and a frequency of 120 breaths/min. Airway opening pressure was measured with a differential pressure transducer (model TP-603T; Nihon Kohden) and was recorded continuously with a pen recorder (Nihon Kohden RJG-4124). Stepwise increases in the acetylcholine (diluted in 0.9% saline) dose (520 mg/ml/120 breaths) were given with an ultrasonic nebulizer (NE-U07; Omron Healthcare). The data were expressed as a percentage of the baseline airway pressure and the provocative concentration of acetylcholine aerosol (PC150), the concentration required for the increase in total pulmonary resistance to 150% of its baseline value. A decrease in PC150 represented an increase in airway responsiveness.
Histological assessment and bronchoalveolar lavage
Thirty-six hours after the last aerosol challenge, the lungs were removed and fixed with 4% paraformaldehyde-PBS and embedded in paraffin. The tissues were sectioned and stained with periodic acid-Schiff (PAS) according to a standard protocol. Cellular infiltration and goblet cells hyperplasia in the airway and lung tissues were evaluated by light microscopy. For bronchoalveolar lavage (BAL), mice were given a lethal dose of pentobarbital, and the lungs were gently lavaged with 1 ml of saline via the tracheal cannula. The lavage fluid was centrifuged at 800 rpm for 5 min at 4°C, and the supernatants were collected for determination of cytokines with ELISA kits (R&D Systems). The cell pellet was resuspended in saline, and cytospin preparations (Cytospin 3; Shandon) were made. Total cell counts and differential cell counts on 200 cells were performed.
Determination of Ag-specific Abs in serum
The amounts of total or Ag-specific IgG1, IgG2a, and IgE in serum were measured by ELISA. For total Ig determination, ELISA plates were coated with anti-mouse IgG1 (AMI2311; BioSource International), anti-mouse IgG2a (A90107A; Bethyl), or anti-mouse IgE (MCA419, Serotec) after 1/500, 1/1000, and 1/500 dilutions, respectively. Plates were washed three times with PBS containing 0.05% Tween 20 (TPBS), and serum samples were added to the wells after serial dilution in 3% BSA/TPBS. After 1-h incubation at room temperature, wells were washed with TPBS; incubated with biotinylated anti-mouse IgG1 (MCA336B; Serotec), anti-mouse IgG2a (61-0240; Zymed Laboratories), or anti-mouse IgE (MCA420B; Serotec) after 1/4000, 1/5000, and 1/2000 dilutions, respectively, for 1 h at room temperature; washed with TPBS; and incubated with streptavidin-conjugated HRP (1/5000 dilution; 43-8323; Zymed) for 20 min. The reaction was developed with OPD (Wako Pure Chemical). For OVA-specific Ig determination, ELISA plates were coated with OVA (50 µg/ml) and blocked with blocking buffer (PBS containing 3% BSA). Detection of each Ig subclass was performed similarly.
RT-PCR analysis
Thirty-six hours after the last OVA challenge, total RNA was isolated from lung tissue or purified draining lymph node (LN) CD4+ T lymphocytes using TRIzol reagent (Invitrogen Life Technologies) and reverse transcribed to cDNA with random primers. RT-PCR were performed using following appropriate pairs of primers (sense and antisense): IL-5, 5'-CTC TAG TAA GCC CAC TTC TA-3' and 5'-TGA TAC CTG AAT AAC ATC CC-3'; IL-10, 5'-TAC CTG GTA GAA GTG ATG CC-3' and 5'-CAT CAT GTA TGC TTC TAT GC-3'; IL-13, 5'-CTC CCT CTG ACC CTT AAG GAG-3' and 5'-GAA GGG GCC GTG GCG AAA CAG-3'; Muc5ac, 5'-CAG CCG AGA GGA GGG TTT GAT CT-3' and 5'-AGT CTC TCT CCG CTC CTC TCA AT-3'; suppressor of cytokine signaling 1 (SOCS1), 5'-CAC TCA CTT CCG CAC CTT CC-3' and 5'-CAG CCG GTC AGA TCT GGA AG-3'; SOCS3, 5'-GTT GAG CGT CAA GAC CCA GT-3' and 5'-GGG TGG CAA AGA AAA GGA G-3'; WSX-1, 5'-ACC ATT GGA GTA TGT GGT GGA CTG-3' and 5'-CTC CTT GAT GTA AGG TTG CCC AGA-3'; p28, 5'-CTG GTA CAA GCT GGT TCC TG-3' and 5'-CTC CAG GGA GTG AAG GAG CT-3'; and EBI3, 5'-CAG AGT GCA ATG CCA TGC TTC TC-3' and 5'-CTG TGA GGT CCT GAG CTG AC-3'. Primer sequences for other cytokines were described previously (26). As an internal control for RNA input and reverse transcripts, we measured the level of
-actin mRNA expression with real-time PCR (ABI PRISM 7000; Applied Biosystems).
Ag-induced cytokine production by peribronchial CD4+ T lymphocytes
Draining LNs were removed from OVA-sensitized mice 36 h after the last OVA challenge, and a single-cell suspension was prepared. Then CD4+ T lymphocytes were purified by MACS (Miltenyi Biotec). CD4+ T cells (1 x 105/well) were cultured in the presence of irradiated (30 Gy) syngeneic spleen cells (1 x 106/well) and OVA (0, 50, and 500 mg/ml). The supernatants from 96-h stimulation cultures were collected and analyzed for the production of IFN-
, IL-4, IL-5, and IL-13 using ELISA development kits (Genzyme Techne). After the 96-h cultivation, cells were incubated for 6 h with [3H]thymidine (MP Biomedicals), added at a final concentration of 1 µCi/well, and then incorporated radioactivity was measured with a 1205 Betaplate (Wallac/PerkinElmer).
Data analysis
Values were expressed as the mean ± SEM. Differences among groups were analyzed using unpaired t tests or an ANOVA together with a Student-Newman-Keuls analysis. Nonparametric data were analyzed using the Kruskal-Wallis test, followed by the Mann-Whitney U test. A value of p < 0.05 was considered significant.
| Results |
|---|
|
|
|---|
AHR is one of the main features of bronchial asthma (1). Therefore, we assessed the airway reactivity of WSX-1/ mice to acetylcholine after immunization and aerosol challenge with OVA. Airway responsiveness to acetylcholine was slightly increased in OVA-challenged WT mice compared with untreated naive WT mice (Fig. 1A), showing that these mice were successfully sensitized to OVA by the immunization protocol used in this study. There were no significant differences in baseline airway responsiveness between naive WT and WSX-1/ mice (Fig. 1A). In OVA-challenged WSX-1/ mice, airway responsiveness to acetylcholine was significantly enhanced over the OVA-challenged WT mice (Fig. 1A). Accordingly, the PC150 was significantly lower in challenged WSX-1/ mice than in challenged WT mice. These results clearly demonstrated that the WSX-1 deficiency enhanced AHR after Ag sensitization. In Fig. 1B, the expressions of WSX-1, p28 of IL-27, and EBI-3 of IL-27 in the lung during the time course of asthma development are shown. Although the expression of WSX-1 and p28 appeared constant, expression levels of EBI-3 were up-regulated after OVA challenge, indicating possible involvement of IL-27/WSX-1 in asthma development.
|
Lung-localized inflammation is also a feature of bronchial asthma (1). As shown in Fig. 2A, PAS staining of lung tissues revealed that histological asthmatic features were also exacerbated in the lungs of OVA-challenged WSX-1/ mice. In naive WT nor WSX-1/ mice, there were no apparent pathological changes in the lung (Fig. 2, A-i and A-iii). However, after OVA challenge, cellular infiltration and goblet cell hyperplasia at bronchiole were apparent in WSX-1/ mice, whereas only mild pathological changes were observed in WT mice (compare Fig. 2, A-ii and A-iv). As shown in Fig. 2A-viii, massive PAS-positive regions were detected under the epithelium and in the lumen of bronchioles of OVA-challenged WSX-1/ mice, whereas minimum PAS-positive regions were observed in the lungs of WT mice (compare Fig. 2, A-vi and A-viii). Furthermore, enhanced expression of Muc5ac mRNA, another marker of goblet cell hyperplasia (27), was detected especially in the lungs of OVA-challenged WSX-1/ mice (Fig. 2B). Additionally, cell counts from BAL fluid revealed that infiltration of inflammatory cells, such as lymphocytes and eosinophils, into the bronchoalveolar space was significantly augmented in OVA-challenged WSX-1/ mice compared with that in WT mice (Fig. 2C). There was no significant difference in the number of macrophages and neutrophils between OVA-challenged wild-type and WSX-1/ mice (Fig. 2C). Therefore, WSX-1 deficiency resulted in severe lung inflammatory changes with eosinophilic infiltration into bronchioles.
|
The concentration of serum IgE Abs is closely associated with the severity of asthma, especially in children (28). The production of subclasses of Igs is regulated by cytokines derived mainly from Th cells. The Th2 cytokine IL-4 induces IgG1 and IgE production, whereas the Th1 cytokine IFN-
induces IgG2a in mice (29, 30). First, we measured total Ig levels in sera from OVA-sensitized (but not challenged) mice as shown in Fig. 3A. In sensitized WSX-1/ mice, total IgE levels were higher than those in sensitized WT mice, and inversely, total IgG2a levels were lower (Fig. 3A). Similar serum Ig profiles were observed in naive WSX-1/ mice before sensitization (Fig. 3B, upper panels). Hence, WSX-1/ mice were likely to be somewhat Th2 prone even in the baseline state before OVA airway challenge. Next, we assessed serum Ig levels from OVA-sensitized mice after challenge. As shown in Fig. 3B (upper panels), total IgG1 and IgE levels were significantly higher in OVA-challenged WSX-1/ mice than in challenged WT mice. In response to OVA challenge, all OVA-specific IgG1, IgG2a, and IgE in sera increased in both WT and WSX-1/ mice, as shown in Fig. 3B (lower panels). Especially, OVA-specific IgE levels in sera of OVA-challenged WSX-1/ mice were significantly higher than those in challenged WT mice, whereas IgG1 and IgG2a levels were not significantly different between the two groups 36 h after the last OVA inhalation. Serum levels of Ag-specific Ig were negligible in both naive WT and naive WSX-1/ mice.
|
Next we determined whether the enhanced AHR and lung inflammation in WSX-1/ mice reflected altered cytokine profiles in OVA-challenged mice. There were barely detectable levels of IL-4, IL-13, and IFN-
in BAL samples from both naive WT and naive WSX-1/ mice (Fig. 4). By OVA challenge, significantly higher amounts of IL-4 and IL-13 were produced in both mouse groups. The levels of IL-4 and IL-13 in BAL samples from OVA-challenged WSX-1/ mice were significantly higher than those in samples from challenged WT mice. In contrast, the level of IFN-
was barely detectable in both WSX-1/ and WT mice before OVA challenge and were not increased even after challenge (Fig. 4). These data clearly demonstrated augmented Th2 cytokine production in the lungs of WSX-1/ mice, especially IL-13, which is likely to participate in severe asthmatic phenotypes in the mice.
|
WSX-1 is highly expressed on CD4+ T lymphocytes (17, 18, 19), which produce various immunoregulatory cytokines. Therefore, we investigated cytokine expression in peribronchial LN CD4+ T lymphocytes purified from OVA-challenged mice by RT-PCR (Fig. 5A). As expected, the expressions of IL-4, IL-5, and IL-13 were enhanced after OVA challenge in both WT and WSX-1/ mice. In challenged WSX-1/ mice, however, these cytokines were overexpressed compared with those in challenged WT mice. Interestingly, the expression of IFN-
was also augmented in WSX-1/ mice after the OVA challenge, whereas it was down-regulated in WT mice after challenge. The expressions of IL-10 and TGF-
, two well-known immunosuppressive cytokines (31, 32), were not significantly altered.
|
production by WSX-1/ T cells was significantly higher than that by wild-type T cells. However, the amounts of IFN-
produced were much lower than the levels of Th2 cytokines produced. Taken together with the results in Fig. 4, it was demonstrated that WSX-1 deficiency resulted in augmented production of Th2 cytokines, including IL-4 and IL-13, and also production of IFN-
. Given the very low amounts of IFN-
produced by WSX-1/ CD4+ T cells or accumulated in BAL after challenge, however, the overproduction of mainly Th2 cytokines caused by WSX-1 deficiency should predominantly affect the exacerbation of AHR and asthmatic pathology in the knockout mice.
Enhanced IFN-
production in WSX-1/ CD4+ T cells was independent of T-bet expression
Among transcription factors, GATA-3 and T-bet function as master regulators for Th2 and Th1 development, respectively (33, 34). The expression of GATA-3 is reportedly increased in patients with atopic asthma (35). Inconsistent with this, the expression of GATA-3 in peribronchial LN CD4+ T cells from OVA-challenged mice was augmented over that in naive mice of both groups (Fig. 6). The expression levels of GATA-3, however, were comparable between WT and WSX-1/ mice. In contrast, the expression of T-bet, which contributes to the induction of IFN-
production, was greatly reduced in WSX-1/ mice after OVA challenge, which was significantly lower than that in OVA-challenged WT mice (Fig. 6). This was apparently contradictory to the overproduction of IFN-
by WSX-1/ T cells (Fig. 5). Therefore, in the current experimental circumstance, WSX-1 is likely to participate in the down-regulation of IFN-
production by CD4+ T cells through a T-bet-independent pathway.
|
Most cytokine signaling pathways leading to cellular activation, including gene expression, are negatively regulated by suitable SOCS (36). Although SOCS are mainly involved in the down-regulation of immune responses (36), some SOCS molecules are implicated in Th1/Th2 responses (37, 38). In this context, we assessed the expression of SOCS1 and SOCS3 in peribronchial LN CD4+ T lymphocytes isolated 36 h after the last OVA challenge. Although SOCS1 was induced after OVA challenge in both WT and WSX-1/ mice, there was no significant difference in the expression levels between WSX-1/ and WT T cells (Fig. 7). Although SOCS3 was also induced by OVA challenge, the expression levels were again comparable between the two groups (Fig. 7). Therefore, SOCS1 and SOCS3 were not implicated in the cytokine overproduction by WSX-1-deficient T cells in the current experimental system.
|
| Discussion |
|---|
|
|
|---|
Given the Th1-promoting property of IL-27/WSX-1 (18, 19, 20, 21), we initially hypothesized that asthma phenotypes in WSX-1/ mice should be worse than those in WT mice simply due to the lack of Th1-mediated suppression of Th2 cytokine production. Although WSX-1/ mice challenged with OVA indeed produced more Th2 cytokines than WT mice, the enhanced production of these Th2 cytokines in WSX-1/ mice is not likely due to the lack of WSX-1-mediated Th1 induction, because IFN-
production was also augmented in WSX-1/ mice (Fig. 5). Because the absolute IFN-
level was extremely low, the enhanced cytokine production in WSX-1/ mice in toto resulted in Th2 predominance and the exacerbated pathogenesis of experimental asthma. The augmented various cytokine production by WSX-1-deficient lymphocytes observed in the current study was reminiscent of our previous studies in which WSX-1/ mice infected with protozoa produced more proinflammatory cytokines than WT mice (23, 24). Thus, WSX-1 contributes to attenuation of allergic pulmonary inflammation during asthma development by its suppressive effect on Th2 cytokine production, a distinct mechanism from its role in Th1 promotion. Similar findings concerning the cytokine profile were observed in the Trichuris muris infection model, which is a well-characterized experimental model for Th2-mediated immune responses. WSX-1-deficient mice infected with T. muris showed augmented Th2 cytokine production with unimpaired IFN-
production by CD4+ T cells as well as intestinal goblet cell hyperplasia (39, 40).
Consistent with the cytokine profiles, OVA-challenged WSX-1/ mice showed higher serum levels of Th2-type IgE than challenged WT mice (Fig. 3). Th2-skewed total Ig profiles were seen in mice with OVA sensitization before challenge and also in naive mice. Thus, even before sensitization or challenge, WSX-1/ mice are prone to Th2 responses, presumably in response to environmental Ags and/or autoantigens. However, in WSX-1/ mice, neither asthmatic phenotypes nor pathological changes were observed before OVA challenge (Figs. 13). Thus, unlike T-bet deficiency (41), deficiency of WSX-1 did not cause spontaneous progression of asthmatic symptoms despite the baseline Th2 inclination. IFN-
production by WSX-1/ lymphocytes was unexpectedly augmented in response to OVA challenge even when T-bet expression was suppressed in knockout mice (Figs. 5 and 6). Therefore, the underlying regulatory mechanisms for the asthmatic phenotypes observed in WSX-1/ and T-bet/ mice appeared distinct. Similarly, GATA-3 does not seem to be involved in the overproduction of Th2 cytokines by WSX-1/ lymphocytes, because the expression of GATA-3 was comparable between the two groups of mice (Fig. 6). Thus, the overproduction of both Th1- and Th2-type cytokines by WSX-1/ cells is presumably caused by mechanisms different from T-bet- or GATA-3-mediated Th differentiation.
The molecular basis for the suppressive function of WSX-1 is currently unknown, but appears independent from IL-10 or TGF-
(Fig. 5A), as in our previous reports (23, 24, 42). Activations of most cytokine receptors are followed by induction of feedback regulators, including SOCS family proteins. SOCS1 is known to suppress IL-4 signal transduction (43), whereas SOCS3 is predominantly expressed in Th2 cells and enhances Th2 development and airway responsiveness after OVA sensitization (38). However, the expression levels of SOCS1 and SOCS3 in peripheral LN CD4+ T cells from OVA-challenged mice were similar in WSX-1/ and WT T cells, as shown in Fig. 7. Therefore, these inhibitory immunomodulators are not likely to be essentially involved in the suppressive function of WSX-1 in the current asthmatic model.
WSX-1/ CD4+ T cells from T. gondii was reportedly hyperproliferative and resulted in the hyperproduction of inflammatory cytokines in mice (23). Furthermore, Artis et al. (40) demonstrated that augmented proliferation of WSX-1/ T cells is likely to contribute to their accelerated Th2 immune response against T. muris infection. Correspondingly, proliferation of CD4+ T cells from OVA-challenged WSX-1/ mice was significantly augmented compared with that of WT T cells (Fig. 5A). Thus, the Ag-specific hyperproliferation of WSX-1/ CD4+ T cells may considerably contribute to the augmented Th2 cytokine production in OVA-challenged WSX-1/ mice. In contrast, Ag-induced proliferation of mesenteric LN CD4+ T cells from WSX-1/ mice after OVA sensitization (but no challenge) was not augmented over that of WT T cells (data not shown). Similarly, OVA-specific cytokine production by mesenteric LN CD4+ T cells after sensitization was generally comparable between WSX-1/ and WT T cells. These results suggested that WSX-1 was principally involved in attenuation of excessive effector functions during secondary responses, but not in regulation of primary responses. During the secondary responses to OVA challenge, not only CD4+ T cells, but various types of cells, including mast cells and eosinophils, are involved in the pathogenesis of asthma. Although there was no significant difference in the number of mast cells in the lung between WT and WSX-1/ mice (not shown), the functions of mast cells as well as other types of cells might be affected in the absence of WSX-1 (40).
IL-27 has been reported as a ligand for WSX-1, and its expression in dendritic cells (DC) is increased when DC are stimulated with LPS (20). A recent study demonstrated that airway Th2 responses induced by injection of OVA-pulsed DC and subsequent aerosolized OVA challenge were suppressed when DC are stimulated with LPS (44). The capacity of LPS to reduce Th2-dependent airway inflammation is independent of IL-12 (44). Therefore, it is plausible that IL-27 derived from LPS-stimulated DC exerts an attenuating effect on asthma development by binding to and activating WSX-1. In the current study the expression level of EBI3 (a subunit for IL-27) in the lung increased during the course of OVA sensitization and challenge (Fig. 1B). Thus, IL-27/WSX-1, rather than IL-12/IL-12R, may be a key inhibitory factor for the pathogenesis of asthma, and as such, it is expected that IL-27/WSX-1 will be a potent target for therapeutic intervention of allergic asthma. The in vivo effect of IL-27 on asthma development is currently under investigation. In conclusion, we demonstrated in this study that WSX-1 deficiency gave rise to severe AHR and lung inflammation in a murine asthmatic model. WSX-1 is critically involved in the attenuation of Th2 cytokine production, independently from Th differentiation. Additional analyses of the in vivo role of IL-27/WSX-1 may eventually reveal their potential for asthma therapy.
| Acknowledgments |
|---|
| Disclosures |
|---|
|
|
|---|
| Footnotes |
|---|
1 This work was supported in part by grants from the Ministry of Education, Science, Technology, Sports and Culture of Japan (to H.Y., H.I., and A.Y.), the Mochida Memorial Foundation of Medical and Pharmaceutical Research (to H.Y.), the Japan Research Foundation for Clinical Pharmacology (to H.Y.), and Novartis Foundation Japan for the Promotion of Science (to H.I.). ![]()
2 Address correspondence and reprint requests to Dr. Hiroki Yoshida, Department of Biomolecular Sciences, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga 849-8501, Japan. E-mail address: yoshidah{at}med.saga-u.ac.jp ![]()
3 Abbreviations used in this paper: AHR, airway hyper-responsiveness; BAL, bronchoalveolar lavage; DC, dendritic cell; EBI3, EBV-induced gene 3; LN, lymph node; PAS, periodic acid-Schiff; PC150, provocative concentration of acetylcholine aerosol; SOCS; suppressor of cytokine signaling; TPBS, Tween-PBS; WT, wild type. ![]()
Received for publication December 6, 2004. Accepted for publication June 6, 2005.
| References |
|---|
|
|
|---|
regulates antigen-induced eosinophil recruitment into the mouse airways by inhibiting the infiltration of CD4+ T cells. J. Exp. Med. 177: 573-576.
regulate allergic airway inflammation and mucus production. J. Exp. Med. 190: 1309-1318.
2a gene: structure and induction by IFN-
. Int. Immunol. 5: 885-891.
in T-cell biology. Nat. Rev. Immunol. 2: 46-53. [Medline]
This article has been cited by other articles:
![]() |
A. V. Villarino, D. Artis, J. S. Bezbradica, O. Miller, C. J. M. Saris, S. Joyce, and C. A. Hunter IL-27R deficiency delays the onset of colitis and protects from helminth-induced pathology in a model of chronic IBD Int. Immunol., June 1, 2008; 20(6): 739 - 752. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Wang, Y. Miyazaki, Y. Shinozaki, and H. Yoshida Augmentation of Antigen-Presenting and Th1-Promoting Functions of Dendritic Cells by WSX-1(IL-27R) Deficiency J. Immunol., November 15, 2007; 179(10): 6421 - 6428. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Yoshimoto, T. Yoshimoto, K. Yasuda, J. Mizuguchi, and K. Nakanishi IL-27 Suppresses Th2 Cell Development and Th2 Cytokines Production from Polarized Th2 Cells: A Novel Therapeutic Way for Th2-Mediated Allergic Inflammation J. Immunol., October 1, 2007; 179(7): 4415 - 4423. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. C. Fitzgerald, B. Ciric, T. Touil, H. Harle, J. Grammatikopolou, J. D. Sarma, B. Gran, G.-X. Zhang, and A. Rostami Suppressive Effect of IL-27 on Encephalitogenic Th17 Cells and the Effector Phase of Experimental Autoimmune Encephalomyelitis J. Immunol., September 1, 2007; 179(5): 3268 - 3275. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Molle, M. Nguyen, V. Flamand, J. Renneson, F. Trottein, D. De Wit, F. Willems, M. Goldman, and S. Goriely IL-27 Synthesis Induced by TLR Ligation Critically Depends on IFN Regulatory Factor 3 J. Immunol., June 15, 2007; 178(12): 7607 - 7615. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. G. Shainheit, R. Saraceno, L. E. Bazzone, L. I. Rutitzky, and M. J. Stadecker Disruption of Interleukin-27 Signaling Results in Impaired Gamma Interferon Production but Does Not Significantly Affect Immunopathology in Murine Schistosome Infection Infect. Immun., June 1, 2007; 75(6): 3169 - 3177. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. G. Perrigoue, J. Li, C. Zaph, M. Goldschmidt, P. Scott, F. J. de Sauvage, E. J. Pearce, N. Ghilardi, and D. Artis IL-31-IL-31R interactions negatively regulate type 2 inflammation in the lung J. Exp. Med., March 19, 2007; 204(3): 481 - 487. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Liu, X. Guan, and X. Ma Regulation of IL-27 p28 gene expression in macrophages through MyD88- and interferon-{gamma}-mediated pathways J. Exp. Med., January 22, 2007; 204(1): 141 - 152. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. C. El Kasmi, J. Holst, M. Coffre, L. Mielke, A. de Pauw, N. Lhocine, A. M. Smith, R. Rutschman, D. Kaushal, Y. Shen, et al. General Nature of the STAT3-Activated Anti-Inflammatory Response J. Immunol., December 1, 2006; 177(11): 7880 - 7888. [Abstract] [Full Text] [PDF] |
||||
| |||||